Header Logo

Connection

JULIE NANGIA to Humans

Back to Details
This is a "connection" page, showing publications JULIE NANGIA has written about Humans.
JULIE NANGIA
Connection Strength
0.173
Humans
  1. Breast Cancer Prevention: Where Are We? JCO Oncol Pract. 2021 12; 17(12):720-722.
    View in: PubMed
    Score: 0.021
  2. Quality of Life Matters: It Is Time to Integrate Scalp Cooling in Routine Clinical Practice. J Oncol Pract. 2018 03; 14(3):157-158.
    View in: PubMed
    Score: 0.016
  3. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
    View in: PubMed
    Score: 0.015
  4. Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr; 12(4):491-501.
    View in: PubMed
    Score: 0.011
  5. Multiple myeloma with multiple extramedullary plasmacytomas. Clin Adv Hematol Oncol. 2011 Aug; 9(8):630-2.
    View in: PubMed
    Score: 0.010
  6. Multilevel barriers and supportive care preferences of metastatic breast cancer patients and their caregivers: a mixed-methods analysis. Support Care Cancer. 2025 Feb 11; 33(3):177.
    View in: PubMed
    Score: 0.007
  7. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024 Nov; 35(11):993-1002.
    View in: PubMed
    Score: 0.006
  8. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
    View in: PubMed
    Score: 0.006
  9. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. 2022 12 12; 40(12):1521-1536.e7.
    View in: PubMed
    Score: 0.006
  10. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
    View in: PubMed
    Score: 0.006
  11. Prognostic Impact of Radiation Therapy in Pure Mucinous Breast Carcinoma. Clin Breast Cancer. 2022 10; 22(7):e807-e817.
    View in: PubMed
    Score: 0.006
  12. Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
    View in: PubMed
    Score: 0.006
  13. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1258-1267.
    View in: PubMed
    Score: 0.005
  14. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 05 01; 26(9):2111-2123.
    View in: PubMed
    Score: 0.005
  15. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.005
  16. Clinical presentation, national practice patterns, and outcomes of breast adenomyoepithelioma. Breast J. 2020 04; 26(4):653-660.
    View in: PubMed
    Score: 0.005
  17. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
    View in: PubMed
    Score: 0.005
  18. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
    View in: PubMed
    Score: 0.004
  19. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
    View in: PubMed
    Score: 0.004
  20. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
    View in: PubMed
    Score: 0.004
  21. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019 May; 80(5):1179-1196.
    View in: PubMed
    Score: 0.004
  22. A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prev Res (Phila). 2018 04; 11(4):203-214.
    View in: PubMed
    Score: 0.004
  23. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21(12):2771-9.
    View in: PubMed
    Score: 0.003
  24. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
    View in: PubMed
    Score: 0.003
  25. Jejunal intussusception due to malignant phyllodes tumor of the breast. Clin Breast Cancer. 2012 Jun; 12(3):219-21.
    View in: PubMed
    Score: 0.003
  26. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
    View in: PubMed
    Score: 0.002
  27. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis. 2005 Jan; 10(1):233-43.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.